First Tracks Biotherapeutics reports positive Phase 1b ANB033 results in celiac disease
On Oct. 12 2026 First Tracks Biotherapeutics presented top‑line data from Cohort 1 of its Phase 1b ANB033 trial in celiac disease. The study of 32 patients (17 on ANB033, 15 on placebo) showed statistically significant improvements in villus height‑to‑crypt depth ratio and intra‑epithelial lymphocyte density, as well as symptom scores, with no serious adverse events. The company said the data support advancing ANB033 to a late‑stage trial in 2027 and that the FDA has already granted Fast Track designation.
Why it matters
The positive data triggered a pre‑market rally of about 20% in TRAX shares. Wells Fargo analysts raised their price target to $62. The results also extend the company’s cash runway by potentially attracting additional funding for the planned 2027 late‑stage trial.
Key facts
- 1The top‑line results were released on Oct. 12 2026 during a webcast at 8:30 a.m. ET. rttnews.com
- 2Cohort 1 enrolled 32 patients, with 17 receiving ANB033 and 15 receiving placebo. finance.yahoo.com
- 3ANB033 produced a least‑squares mean change in Vh:Cd ratio of –0.17 versus –0.66 for placebo, a placebo‑adjusted delta of +0.49 (p = 0.009). stocktitan.net
- 4ANB033 produced a least‑squares mean change in IEL density of –1.20 versus +18.83 for placebo, a placebo‑adjusted delta of –20.03 (p < 0.001). stocktitan.net
- 5No serious adverse events or severe adverse events were reported in the trial. finance.yahoo.com
- 6TRAX shares rose roughly 20% in pre‑market trading after the announcement. finance.yahoo.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.